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We aimed to compare bone-marrow-derived mesenchymal stem cells (BMMSCs) between systemic lupus erythematosus (SLE)
and normal controls by means of cDNA microarray, immunohistochemistry, immunofluorescence, and immunoblotting. Our
results showed there were a total of 1, 905 genes which were diﬀerentially expressed by BMMSCs derived from SLE patients,
of which, 652 genes were upregulated and 1, 253 were downregulated. Gene ontology (GO) analysis showed that the majority
of these genes were related to cell cycle and protein binding. Pathway analysis exhibited that diﬀerentially regulated signal
pathways involved actin cytoskeleton, focal adhesion, tight junction, and TGF-β pathway. The high protein level of BMP-5 and
low expression of Id-1 indicated that there might be dysregulation in BMP/TGF-β signaling pathway. The expression of Id-1 in
SLE BMMSCs was reversely correlated with serumTNF-α levels. The protein level of cyclin E decreased in the cell cycling regulation
pathway. Moreover, the MAPK signaling pathway was activated in BMMSCs from SLE patients via phosphorylation of ERK1/2 and
SAPK/JNK. The actin distribution pattern of BMMSCs from SLE patients was also found disordered. Our results suggested that
there were distinguished diﬀerences of BMMSCs between SLE patients and normal controls.
1. Introduction
Systemic lupus erythematosus (SLE) is a chronic autoim-
mune disease characterized by multiorgan involvement
including renal, cardiovascular, neural, musculoskeletal, and
cutaneous systems and remarkable variability in clinical pre-
sentation and the etiopathogenesis of SLE remains unclear
[1]. In recent years, several studies suggest that SLE may be
identified as a stem cell disorder, the etiopathogenesis of this
autoimmune disease is attributable to defects in the bone
marrow microenvironment, mainly in the hematopoietic
stem cells (HSCs) [2], and the bone marrow transplantation
(BMT) has a curative eﬀect on systemic autoimmune disease
in (NZB × NZW) F1, BXSB, and (NZW × BXSB) F1 mice
[3, 4].
Stromal cells in bone marrow, also called bone-marrow-
derived mesenchymal stem cells (BMMSCs), are one of
important components of bone marrow microenvironment,
which play a crucial role in the growth, diﬀerentiation,
and function of HSCs [5]. In addition, BMMSCs can
diﬀerentiate into a variety of cell types including osteoblasts,
chondrocytes, adipocytes, and myoblasts [6–9] and possess
immuno-modulatory properties such as inhibiting T-cell
proliferation in vitro [10, 11]. Studies on animal models
showed BMMSCs from lupus BXSB mice were slower to
grow, less proliferative, and harder to diﬀerentiate into
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Table 1: Demographic data and clinical features of SLE patients for cDNA microarray analysis.
Patient no.
Sex/Age
(yrs)
Disease duration
(months)
SLEDAI Clinical manifestations Therapy
1 F/20 84 14 Nephritis, arthralgia, vasculitis Pred, HCQ, CYC
2 F/44 12 10 Nephritis, arthralgia, cytopenia Pred, HCQ, CYC
3 F/43 240 19 Nephritis, cytopenia, interstitial pneumonia Pred, HCQ, CYC
4 F/42 6 20 Nephritis, cytopenia, interstitial pneumonia, polyserositis Pred, HCQ, CYC
Pred: Prednisone, CYC: Cyclophosphamide, HCQ: Hydroxychloroquine.
osteoblasts compared with those from healthy C57/Bl6 mice,
and the deficiencies were associated with structural alter-
ations in the gap junction protein Cx43 [12]. BMMSCs from
SLE patients have impaired hematopoietic function [13],
demonstrating early signs of senescence [14]. In our previous
study, we reported BMMSCs derived from SLE patients
showed significantly decreased bone-forming capacity and
impaired reconstruction of bone marrow osteoblastic niche
in vivo [15]. Moreover, the mRNA level of IL-6 and IL-7
were downregulated in BMMSCs from SLE patients [16].
So we hypothesize that SLE might not only be a stem
cell disease, but also a BMMSCs disorder. Based on this
hypothesis, in the clinical setting, we intravenously infused
allogenic BMMSC or umbilical cord mesenchymal stem
cell (UCMSC) to SLE patients, the majority of recipients
experienced rapid improvement postinfusion [15, 17–19].
Those studies indicated that, as one of components in
the bone marrow microenvironment, BMMSCs dysfunction
probably partook in the pathogenesis of SLE and correction
of the abnormalities might contribute to the disorder
improvement.
Nonetheless, relatively little is known about the cellu-
lar and molecular mechanisms underlying the control of
mesenchymal stem cell (MSC) proliferation, diﬀerentiation,
and survival. Recent results have demonstrated multiple
signaling pathways involved in the functions of MSCs. For
example, the osteogenic diﬀerentiation of MSCs induced by
bone morphogenetic proteins-2 (BMP-2) may be mediated
by coordinated activation of Notch, Wnt, and transforming
growth factor-β (TGF-β) signaling pathways [20]; MSCs
were activated by TLR ligands leading to modulation of
the diﬀerentiation, migration, proliferation, survival, and
immunosuppression capacities [21–23]. But the studies
concerning pathways involved in the deficiency of BMMSCs
from SLE patients are almost blank.
In this study, using the microarray assay, we firstly found
that there were significant diﬀerences in gene expression
profile (GEP) of BMMSCs between SLE patients and normal
controls. And in the further investigation, we confirmed that
there were abnormalities in actin cytoskeleton, cell cycling
regulation, BMP/TGF-β, and MAPK signaling pathways in
BMMSCs from SLE patients.
2. Materials and Methods
2.1. Patients and Controls. Bone marrow (BM) was obtained
for cDNA microarray from 4 SLE patients according to the
American College of Rheumatology criteria [24]. All were
female, and the mean age was 37 ± 11 years (range 20∼44).
The demographic data and clinical features of SLE patients
were listed in Table 1. The normal controls were 1 male and
3 females, with a mean age of 39 ± 7 years (range 29∼45).
Further qRT-PCR was performed from 10 female patients
(mean 40 ± 14 years, range 15∼60 years) and 10 female
normal controls (mean 41 ± 14 years, range 24∼65 years).
All SLE patients had active disease with a SELENA-SLEDAI
(Systemic Lupus Erythematosus Disease Activity Index) [25]
score of more than 10 at the time of bone marrow aspiration.
All participants gave written consent to the study which was
approved by the Ethics Committee of the Aﬃliated Drum
Tower Hospital of Nanjing University Medical School.
2.2. Cell Culture and Flow Cytometry. BM was taken from
the iliac crest of SLE patients and normal controls, resus-
pended by phosphate-buﬀered saline (PBS), and then lay-
ered over 1.077 g/mL Ficoll (TBD, Tianjin, China) solution
before being centrifuged at 600×g for 20 minutes at
room temperature. The mononuclear cells were collected
and resuspended in low glucose Dulbecco Modified Eagle
Medium (L-DMEM, Gibco) supplemented with 10% heat
inactivated fetal bovine serum (FBS, Invitrogen, USA) and
1% antibiotic-antimycotic solution and plated at a density of
2×107 cells per 25 cm-dish. The cultures were maintained at
37◦C in a 5% CO2 incubator, and the medium was changed
after 48 hours and then every three days. When the MSCs
were confluent, the cells were recovered by the addition
of 0.25% trypsin-EDTA (Gibcoth) and then replated at a
density of 1 × 106 cells per 25 cm dish. Cells at passage 3
were consequently analyzed by flow cytometry as described
previously [16].
2.3. Microarray Hybridization. BMMSCs were placed in
Trizol (Invitrogen, USA) and processed for RNA extraction
using the RNeasy kit according to the instructions of the
manufacture (Qiagen, Valencia, CA). The universal human
reference RNA samples which comprised of 10 diﬀerent cell
lines of humans (Stratagene Corporation, USA) were used
as a common reference in the two channel microarray. Total
RNA was reverse transcribed, and the cDNA of BMMSCs
from SLE patients and normal controls was added with
Cy3-dCTP while the cDNA of human reference was added
with Cy5-dCTP in the present with Klenow enzyme (GE
Healthcare Cat. Nos. PA 55021/PA 53021) [26]. Microarray
analysis was performed in CapitalBio Corp (Beijing, China)
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using 22K Human Genome Array. The slide contains
gene-specific 70-mer oligonucleotides representing 21, 329
human genes including four human housekeeping genes
as positive controls and twelve random negative controls
that are designed to have no significant homology with
known human DNA sequences as negative controls. Labeled
samples were quantitatively adjusted based on the eﬃciency
of Cy-dye incorporation and mixed into 80 μL hybridization
solution (3 × SSC, 0.2% SDS, 25% formamide, and 5 ×
Denhart’s). DNA in hybridization solution was denatured
at 95◦C for 3min prior loading on a microarray. The array
was hybridized at 42◦C overnight and washed with two
consecutive washing solutions (0.2% SDS, 2 × SSC at 42◦C
for 5min, and 0.2% SSC) for 5min at room temperature.
Finally, arrays were scanned with a confocal LuxScan 10KA
scanner (CapitalBio). The data of obtained images were
extracted with LuxScan 3.0 software (CapitalBio). Genes
with the signal intensity more than 800 (Cy3 or Cy5)
were regarded as the expressed ones. In every two channel
slides, the intensity ratio of the Cy3 to Cy5 of each spot
was calculated after normalization with LOWESS regression.
Statistical data and diﬀerential analysis files were generated
by using SAM software 3.0 (Stanford University, Stanford,
CA, USA). The significant changed genes were selected
based on P value < 0.05 and >2-fold as criteria. All the
diﬀerentially expressed genes were analyzed using a free
web-based Molecular Annotation System 2.0 (MAS 2.0,
http://bioinfo.capitalbio.com/mas3/) [27, 28].
All data is MIAME compliant and that the raw data
has been deposited in a MIAME compliant database (GEO).
The raw data can be seen http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE21649. The accession number is GSE
21649.
2.4. Quantitative Reverse Transcription-Polymerase Chain
Reaction. Gene expressions were examined by real time RT-
PCR performed by ABI 7500 FAST real-time PCR detec-
tion system (Applied Biosystems, USA) using SYBR Green
detection mix (TaKaRa, Japan) [16]. The expressions of Id
(inhibitor of diﬀerentiation or inhibitor of DNA binding)-1,
Id-2, Id-3, cyclin D, and cyclin E2 were analyzed from 5∼10
samples from other SLE patients and normal controls. The
following primers were used in this study:
GAPDH (sense): 5′-TGACTTCAACAGCGACAC
CCA-3′
(antisense): 5′-CACCCTGTTGCTGTAGCCAAA-3′;
Id-1 (sense): 5′-ACGACATGAACGGCTGTTACT
CAC-3′
(antisense): 5′-CTCCAACTGAAGGTCCCTGATG
TAG-3′;
Id-2 (sense): 5′-TGTCAGCCTGCATCACCAGA-3′
(antisense): 5′-CCACACAGTGCTTTGCTGTCA-3′;
Id-3 (sense): 5′-TCAGCTTAGCCAGGTGGAAATC
-3′
(antisense): 5′-GGCTGTCTGGATGGGAAGGT-3′;
Cyclin D: (sense) 5′-TGATGCTGGGCACTTCAT
CTG-3′
(antisense): 5′-TCCAATCATCCCGAATGAGAGTC
-3′;
Cyclin E2 (sense): 5′-GCCGTTTACAAGCTAAG
CAGCAG-3′
(antisense): 5′-CCAGATAATACAGGTGGCCAA
CAA-3′.
2.5. Immunofluorescence Staining. Cells were washed three
times with PBS, fixed for 10min 3.7% formaldehyde in
PBS, and permeabilized for 5min with 0.2% triton X-100
3.7% formaldehyde. The fixed cells were rehydrated with
Tris buﬀered saline (TBS) and incubated for 1 h in blocking
solution (3% BSA in TBS), then they were incubated with
Alexa Flour 594 conjucted phalloidin (Invitrogen, USA) or
phalloidin-FITC (Sigma, USA) antibodies for 1 h at 37◦C.
Nuclei were counterstained with DAPI (4,6-diamidino-2-
phenylindole). Finally, cells were rinsed in TBS, mounted
in DABCO/mowiol. Images were acquired using a TCS
SP2 confocal microscope (Leica, Germany) or fluorescence
microscope (Olympus, Japan).
2.6. Immunocytochemistry Staining. Cells were seeded on
poly-L-lysine-coated 6-well chamber slides (BD, Bioscience),
cultivated for another 3 days. Samples were then fixed with
cold acetone for ten minutes followed by incubation in
3% hydrogen peroxide to block the endogenous peroxide
activity. To prevent nonspecific antibody binding, slides were
preincubated for 30min in normal goat serum. Slides were
then incubated with primary monoclonal antibody against
human BMP-5 (Bioword Technology, USA) at 37◦C for 1 h,
followed by incubated with second antibody MaxVision kit
(Maxim Inc., China) for 15min at room temperature. After a
15-min wash, slides were treated with 3,3′-diaminobenzidine
(DAB) for 5min and finally counterstained with hema-
toxylin.
2.7. Immunoblotting. Cells were lysed with sodium dodecyl
sulfate- (SDS-) sample buﬀer containing 0.1M Tris-HCl, 4%
SDS, 0.2% Bromophenol Blue, and 5% β-mercaptoethanol.
Cell lysates were separated by SDS-PAGE and transferred to
a polyvinylidene difluoride (PVDF) membrane (Millipore,
Bedford, MA). Blots were probed by anti-phospho- and anti-
total-extracellular signal-regulated kinase (ERK)1/2 MAPK
antibodies (Cell Signaling Technology Inc.), anti-phospho-
and anti-total-P38 MAPK antibodies (Cell Signaling Tech-
nology Inc.), anti-phospho- and anti-total-stress-activated
protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK)
MAPK antibody (Cell Signaling Technology Inc.), anti-cyclin
D antibodies (Epitomics Inc.), and anti-cyclinE (Epitomics
Inc.) before visualizing with HRP-conjugated secondary
antibodies followed by development with FluorChem FC2
System (Alpha Innotech Corporation, USA).
2.8. ELISA Analysis. Serum from 10 SLE patients and 20
normal controls were collected, and the concentrations of
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Figure 1: Genes diﬀerentially expressed in BMMSCs between SLE
patients and normal controls. Genes were shown by the ratio of
hybridization intensity between normal control and SLE BMMSCs.
The ratio ≥2 or ≤0.5 was considered significant. Genes highly
expressed in BMMSCs from normal controls were highlighted in
green, while those highly expressed in BMMSCs from SLE patients
were highlighted in red.
tumor necrosis factor-α (TNF-α) of each individual were
measured using commercial ELISA kit (R&D) according to
the manufactory introduction.
2.9. Statistical Analysis. Statistical analyses were performed
using SPSS for 16.0. All data were expressed as mean ± SEM.
The relative expression of the target genes in SLE samples as
compared with that in normal controls was examined using
2−ΔΔCt method [29]. Briefly, for each sample, a value for the
cycle threshold (Ct) was determined, defined as the mean
cycle at which the fluorescence curve reached an arbitrary
threshold. The ΔCt for each sample was then calculated
according to the formula Ct target gene-Ct GAPDH; ΔΔCt
values were then obtained by subtracting the ΔCt of a
reference sample (averageΔCt of the control group) from the
ΔCt of the studied samples. Finally, the levels of expression
of the target genes in the studied samples as compared with
the reference sample were calculated as 2−ΔΔCt. A P value of
0.05 or less (P < 0.05) by independent Student’s t test or
nonparametric test was considered statistically significant.
3. Results
3.1. Unsupervised Hierarchical Clustering in the BMMSCs
from SLE Patients and Normal Controls. Firstly, we sought to
investigate whether the gene expression profiles were globally
diﬀerent between BMMSCs from patients with SLE and
normal controls. We used the total number of 8, 769 genes
detected to perform the unsupervised hierarchical clustering
after faint spots were removed. As expected, hierarchical
Table 2: Diﬀerentially expressed genes in regulation of actin cy-
toskeleton and TGF-β signaling between SLE patients and normal
controls.
Upregulated genes in actin cytoskeleton
pathway
Fold P value
ACTN4 2.30 ≤1.0E − 6
ACTB 2.41 ≤1.0E − 6
VAV1 4.08 ≤1.0E − 6
MATK 2.85 ≤1.0E − 6
ITGB5 8.46 ≤1.0E − 6
ITGB4 2.43 ≤1.0E − 6
Downregulated genes in actin cytoskeleton
pathway
KRAS 5.62 ≤1.0E − 6
ARPC3 2.17 ≤1.0E − 6
ARPC4 2.10 ≤1.0E − 6
ARPC5 2.53 ≤1.0E − 6
NRAS 2.01 ≤1.0E − 6
GNG12 2.17 ≤1.0E − 6
NCKAP1 3.16 ≤1.0E − 6
ITGA1 3.63 ≤1.0E − 6
CRKL 2.71 ≤1.0E − 6
ITGB5 2.58 ≤1.0E − 6
PPP1CC 3.36 ≤1.0E − 6
CFL2 2.06 ≤1.0E − 6
ROCK2 2.38 ≤1.0E − 6
PDGFRA 2.77 ≤1.0E − 6
F2R 2.57 ≤1.0E − 6
RDX 2.23 ≤1.0E − 6
PPP1R12A 2.99 ≤1.0E − 6
ARHGEF6 2.31 ≤1.0E − 6
ITGAV 7.84 ≤1.0E − 6
CRK 2.71 ≤1.0E − 6
Upregulated genes TGF-β signaling
BMP5 4.23 ≤1.0E − 6
Downregulated genes TGF-β signaling
SMAD1 2.08 ≤1.0E − 6
SMAD5 2.60 ≤1.0E − 6
SMURF2 2.66 ≤1.0E − 6
ID1 3.81 ≤1.0E − 6
BMPR1A 3.03 ≤1.0E − 6
TGFBR1 4.50 ≤1.0E − 6
TGFBR2 2.01 ≤ 1.0E − 6
ACVR1 3.12 ≤1.0E − 6
CREBBP 2.06 ≤1.0E − 6
ROCK2 2.38 ≤1.0E − 6
RPS6KB1 2.64 ≤1.0E − 6
CDKN2B 2.03 ≤1.0E − 6
THBS1 3.14 ≤1.0E − 6
THBS3 2.11 ≤1.0E − 6
THBS2 3.05 ≤1.0E − 6
LTBP1 2.27 ≤1.0E − 6
COMP 4.89 ≤1.0E − 6
FST 2.23 ≤1.0E − 6
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Figure 2: Classification of the diﬀerentially expressed genes according to the pathway and GO analysis by MAS software. (a) The top 10
statistically significant (P < 0.001) pathways. (b) The top 10 statistically significant (P < 0.001) molecular functions by GO analysis. The
numbers indicated the diﬀerentially expressed genes in the specific pathway or function.
clustering of the 8 BMMSCs samples fell into 2 groups
displaying diﬀerent expression patterns of those 8, 769 genes.
One cluster consisted of samples from SLE patients (samples
1∼4) and the other cluster consisted of those from normal
controls (samples 5∼8, Figure 1). These data suggested the
existence of diﬀerent gene expression patterns of BMMSCs
between SLE patients and normal controls.
3.2. Gene Ontology (GO) and Pathway Analysis of BMMSC.
There were 1, 905 genes found to be diﬀerently expressed
between the SLE patients and the normal controls using
SAM software combined P-value < 0.05 and >2-fold criteria.
Of those genes, 652 were upregulated in the BMMSCs of
SLE patients, while other 1, 253 were downregulated. The
functions of diﬀerentially expressed pathways included actin
cytoskeleton, focal adhesion, TGF-β signaling, and tight
junction. The altered expression of 26 genes was found to
be involved in regulating actin cytoskeleton pathway, among
which 6 genes were up-regulated while 20 down-regulated
in BMMSCs from SLE patients. Interestingly, most genes
in TGF-β signaling pathway were downregulated except for
BMP5. Moreover, GO analysis found that genes involved in
the control of the cell cycle, protein binding, and calcium
ion binding showed the most significant diﬀerences among
gene expression profiles (all P < 0.0001; Figure 2). The dif-
ferentially expressed genes in regulation of actin cytoskeleton
and TGF-β signaling were listed in Table 2. The expressions
of SMAD1, BMPR1A, ACTB, and ARPC5 by microarray
assay were confirmed by qRT-PCR analysis. The four selected
genes were initially validated by qRT-PCR in the RNA
samples used for the microarrays. As expected, the qRT-PCR
data showed significant diﬀerences between SLE patients
and normal controls and confirmed the direction of the
fold changes (supplementary Figure 1; see Supplementary
material available online at doi:10.1155/2012/826182).
3.3. Abnormal Actin Cytoskeleton Distribution Pattern in
BMMSCs from SLE Patients. Consistent with our previous
findings, flow cytometric analysis showed CD29, CD44, and
CD105 expression of >95%, in parallel with CD45, CD34,
CD14, and HLA-DR expression of <5% (supplementary
Figure 2). Although BMMSCs from SLE patients and normal
controls showed similarly fibroblast-like morphology as
observed by light microscopy [16], the actin distribution pat-
tern in BMMSCs from SLE patients, distinct from that from
normal controls (Figure 3(a)), exhibited an irregular and
twisted pattern under fluorescence microscope (Figure 3(b)).
Under confocal microscopy, BMMSCs from normal controls
displayed a pattern of parallel actin stress fibers extending
across the entire cytoplasm as revealed by phalloidin staining
(Figure 3(c)), while F-actin in BMMSCs from SLE patients
was disorganized and condensed on the edge of cytoplasm
(Figure 3(d)).
3.4. Altered Protein Expression in Regulating Cell Cycle. Since
microarray analysis showed altered expression profile of
genes involved in cell cycle, we evaluated the mRNA and
protein levels of cyclin D and cyclin E in samples from 5
SLE patients. No diﬀerence was found in the levels of cyclin
D and cyclin E2 transcripts between BMMSCs from SLE
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Figure 3: Actin distribution patterns in BMMSCs from SLE patients or the normal controls. (a, b) Actin filaments were stained with Alexa
Flour 594 conjucted phalloidin (red) and nuclei were counterstained with DAPI (blue). Cells (white arrows) were observed by fluorescence
microscope. (a): BMMSCs from normal controls, (b): BMMSCs from SLE patients. (magnification ×200) (c, d) Actin filaments was stained
with phalloidin-FITC and observed under confocal microscopy. (c): BMMSC from one normal control, (d): BMMSC from one SLE patient
(Bar = 20).
patients and normal controls. However, immunoblotting
analysis further revealed reduced protein level of cyclin E in
BMMSCs from SLE patients (n = 3, P = 0.003) (Figure 4).
3.5. Abnormal Gene and Protein Expressions in BMP/TGF-
β Signaling Pathway. In addition, we performed immunos-
taining experiments to detect the protein level of BMP-
5, which was the only upregulated gene in BMP/TGF-β
signaling pathway in microarray. Moreover, the expressions
of target gene of BMP signaling pathway, including Id-1, Id-
2, and Id-3, from 10 samples of SLE patients and normal
controls were analyzed by qRT-PCR. Most of BMMSCs
from both normal controls and SLE patients were positively
stained cells. However, BMMSCs from normal controls
showed light brown staining in cytoplasm while BMMSCs
from SLE patients were dark brown stained in both nuclei
and cytoplasma, suggesting that BMP-5 protein expression
was upregulated in BMMSCs from SLE patients. Among the
target genes, only the expression of Id-1 was lower in SLE
(0.89 ± 0.51) compared with normal controls (1.86 ± 1.26)
(n = 10, P = 0.037). The results indicated that the BMP
signaling pathway appeared to be dysregulated in BMMSCs
from SLE patients (Figure 5).
3.6. Activated MAPK Pathway in BMMSCs from SLE Patients.
Another cascade that appeared to be disordered was the
MAPK pathway. As shown in Figure 6, the phosphorylation
of ERK1/2 (n = 3, P = 0.03) and SAPK/JNK (n = 3,
P = 0.03) were higher in BMMSCs from SLE patients,
as compared with normal controls (n = 4), while the
phosphorylation of P38 showed similar levels in BMMSCs
between SLE patients and normal controls, suggesting a
partially activated MAPK pathway in BMMSCs from SLE
patients.
3.7. Id-1 Associated with Serum TNF-α Level in SLE Patients.
In order to identify the relationship between the diﬀerentially
expressed genes and the clinical outcome, correlation analy-
sis was used between Id-1 mRNA levels and serum levels of
antinuclear antibodies (ANAs), TNF-α, and SLEDAI in SLE
patients. The level of TNF-α in the serum of SLE patients
(n = 10) was higher than that in normal controls (n = 20)
(P = 0.006). Id-1 mRNA levels had no correlation with ANA,
Clinical and Developmental Immunology 7
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Figure 4: mRNA and protein levels of cyclin D and cyclin E in BMMSCs from SLE patients. (a) Immunoblotting analysis of cyclin D and
cyclin E. (b) qRT-PCR studies of the expression of cyclin D and cyclin E2 in BMMSCs from SLE and normal controls (n = 5, P > 0.05).
Results were shown as mean ± SEM, each performed with triplicate samples. (c) Quantity analysis showed low protein level of cyclin E in
cells from SLE patients, ∗∗P < 0.01 by Student’s t-test. SLE: systemic lupus erythematosus, Nor: normal controls.
SLEDAI, but it was reversely correlated with serum level of
TNF-α in SLE patients (Figure 7). In addition, Id-1 mRNA
levels of BMMSCs from normal controls had no correlation
with their serum levels of TNF-α (see supplementary Figure
3, n = 10, P = 0.76).
4. Discussion
Previous studies using microarray in SLE examined gene
expression in peripheral blood mononuclear cells (PBMCs)
and showed interferon- (IFN-) inducible and granulopoiesis
signatures correlating with both disease severity and disease
activity [30, 31]. IFN-related genes and genes involved in
extra-cellular matrix (ECM) homeostasis were also found
diﬀerentially expressed in target organs, such as lupus
glomeruli and synovium of SLE patients in some studies
[29, 32]. One study diﬀerentiated active SLE from inactive
by the microarray analysis of the bone marrow mononuclear
cells (BMMCs), and the upregulated genes in SLE patients
were involved in cell death and granulopoiesis [33]. In our
study, genes in regulation of cell cycle, actin cytoskeleton
regulation, TGF-β, focal adhesion, and MAPK pathways,
rather than type I interferon signature were found to be
diﬀerentially expressed in the BMMSCs from SLE patients,
suggesting the distinct role of bone marrow, especially the
stromal cells in regulating the immune response.
Although the morphological characteristics of BMMSCs
from SLE patients was the same as the normal controls [16],
we observed under confocal and fluorescence microscopes in
this study that the F-actin of BMMSCs from SLE patients
was confused and condensed on the edge of cytoplasm,
which was absolutely diﬀerent from normal controls. This
actin distribution of BMMSCs from SLE patients supported
the notion that MSCs from SLE patients tended to be
senescent [8]. Actin filaments form the cytoskeleton with
microtubules and their prokaryotic cousins play central
roles in cell shape, motility, and chromosome segregation
control [34, 35]. Moreover, recent studies found actin
filaments were closely related to the apoptosis, aging, and
malignant transformation of cells [36, 37]. Those studies in
combination with present results indicated that BMMSCs
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Figure 5: Immunohistochemical detection of BMP-5 protein and mRNA levels of Id-1, Id-2, Id-3 in BMMSCs. (a) magnification×100, (b)
magnification×200. The left pictures are isotype controls, the right are BMP-5 immunohistochemical staining. (c) qRT-PCR studies of the
expression of Id-1, Id-2, and Id-3 in BMMSCs from SLE patients and normal controls (n = 10). ∗P < 0.05 by nonparametric test of SPSS
16.0 software. SLE: systemic lupus erythematosus, Nor: normal controls.
from SLE patients might be abnormal in such functions as
migration and aging, which attributes to the disordered actin
cytoskeleton.
According to the gene ontology analysis, the most dif-
ferentially expressed genes were those involved in regulating
the cell cycle, which is consistent with the reports that
BMMSCs from SLE patients showed lower proliferative
capacity compared with normal controls [14, 16]. In this
study, we examined the mRNA and protein levels of only two
members of cyclin family, cyclin D and cyclin E2. Although
no diﬀerence was found in the mRNA level in BMMSCs
between SLE patients and normal control, immunoblotting
analysis demonstrated that the cyclin E expression was lower
in the BMMCs from SLE patients, suggesting a deficiency at
protein level. This deficiency in regulation of cell cycle might
result in the decreased cell proliferative capacity of BMMSCs
in SLE patients.
BMPs are multifunctional growth factors that belong
to the TGF-β superfamily. Studies have shown that BMP
signaling plays critical roles in bone formation and car-
tilage development [38]. Specific BMPs such as BMP-2,
BMP-6, and BMP-9 promote the diﬀerentiation of MSCs
into osteoblasts in vitro [39]. The BMP signaling cascade
initiate from the binding with BMP receptors. Binding of
an extracellular ligand promotes the dimerization of the
two serine/threonine protein kinases. The type-II kinase
phosphorylates the type-I receptor. Activation of the type-
I receptor initiates phosphorylation of downstream eﬀec-
tor proteins, such as receptor-regulated Smads (R-Smads),
including Smad-1, 2, 3, 5, and 8, leading to signal trans-
duction. Following activation, the R-Smad protein forms a
heterooligomeric complex with a common mediator Smad
(Co-Smad; Smad4), which translocates into the nucleus
and regulates the transcription of target genes, such as
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Figure 6: MAPK pathway in BMMSCs from SLE patients. Immunoblotting showed the phosphorylation of JNK and ERK1/2 was higher in
BMMSCs from SLE patients. Results were shown as mean ± SEM. ∗P < 0.05 (SLE versus normal controls by Student’s t-test). SLE: systemic
lupus erythematosus, Nor: normal controls.
Rux2, Msx2, and osterix [40]. According to the results of
the microarray, most of genes in the BMP pathway were
decreased including Smad-1, Smad-5, BMPR1A and the
target gene Id-1. As the phosphorylation process controls
the activity of Smad-1, Smad-5, and BMPR1A, we only
confirmed the mRNA level of some of the target genes and
the protein level of BMP-5.
Id genes are thought to be the most targeted genes by
BMP-Smad signaling. Four Id proteins (Id-1 to -4) have been
identified in mammals, which are critical in controlling the
diﬀerentiation and proliferation of myeloid lineages [41].
Previous studies indicated that Id-3 was overexpressed in
SLE peripheral blood cells [42] and Id-1 transcription was
upregulated by IL-6 stimulation in the B6.Sle1.Yaa mice
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Figure 7: The correlation of Id-1 mRNA expression with serum TNF-α levels in SLE patients. (a, b) Id-1 mRNA level was not correlated
with antinuclear antibodies (ANA) levels and SLE disease activity index (SLEDAI) score of SLE patients. (c) The serum level of TNF-α in SLE
patients (n = 10) were higher than that of normal controls (n = 20). ∗∗P < 0.01 versus normal controls by Student’s t-test. (d) Id-1 mRNA
expression was reversely correlated with serum TNF-α level of SLE patients (P = 0.01, r2 = 0.55). SLE: systemic lupus erythematosus, Nor:
normal controls.
model [43].When compared with normal controls, we found
that the Id-1 mRNA level was lower in BMMSCs derived
from SLE patients, however, its level was not correlated with
ANA level or SLADAI score of SLE patients. Similar to the
results described by others [44, 45], TNF-α level was also
found higher in the serum of SLE patients in our study, which
was reversely correlated with Id-1 mRNA level. This result
further confirmed those of microarray and suggested there
might be a dysregulated BMP pathway in BMMSCs from
SLE patients, which possibly contribute to the osteogenesis
impairment and osteoblastic niche deficiency in MRL/lpr
mice and SLE patients [15].
MAPK cascade is an important pathway that trans-
mits extracellular signals into cytoplasma to initiate cel-
lular processes such as proliferation, diﬀerentiation, and
development. The three well-characterized subfamilies of
MAPKs include the extracellular signal-regulated kinases
(ERK1/2), c-Jun NH2-terminal kinases (JNK-1/2/3), p38.
Many growth factors can trigger MAPK pathway including
epidermal growth factor (EGF), fibroblast growth factor
(FGF), and platelet-derived growth factor (PDGF). In addi-
tion, chemokines such as SDF-1 could stimulate human
MSCs migration through increased phosphorylation of
ERK [46], and Wnt3a could induce a rapid and transient
activation of MAPKs p38 and ERK1/2 leading to increased
alkaline phosphatase activity and nodule mineralization
in murine C3H10T1/2 mesenchymal cells [47]. Moreover,
many inflammatory cytokines, such as IL-1 and TNF-α,
could inhibit the osteoblastic diﬀerentiation via phospho-
rylation of ERK1/2 and SAPK/JNK [48, 49]. We found in
this study an increased phosphorylation of ERK1/2 and
SAPK/JNK in BMMSCs from SLE patients and postulate
that this activation might result from the inflammatory
environment in the bone marrow of SLE patients.
5. Conclusion
In conclusion, our present study revealed absolutely diﬀerent
gene profile pattern of BMMSCs from SLE patients and
showed disordered actin cytoskeleton in BMMSCs from SLE
patients. Furthermore, we found abnormalities in cell cycling
regulation, BMP/TGF-β and MAPK pathways. Our findings
suggest BMMSCs, as a component of bone marrow, may play
an important role in the etiopathogenesis of SLE.
Clinical and Developmental Immunology 11
Conflict of Interests
The authors indicate no potential conflict of interests.
Acknowledgments
The authors thank Professor A. G. Wilson, Department of
Rheumatology, University of Sheﬃeld, UK, for his critical
review of the manuscript. The study was supported by
the Major International (Regional) Joint Research Project
(no. 81120108021), National Natural Science Foundation
of China (no. 30972736); Jiangsu Province Natural Science
Foundation (BK2009034); Jiangsu Province Kejiao Xing-
wei Program, Chinese National 115 Supporting Program
(2008BAI 59B02).
References
[1] D. A. Isenberg and A. Rahman, “Systemic lupus erythemato-
sus,” The New England Journal of Medicine, vol. 358, no. 9, pp.
929–939, 2008.
[2] S. Ikehara, M. Inaba, R. Yasumizu et al., “Autoimmune
diseases as stem cell disorders,” Tohoku Journal of Experimental
Medicine, vol. 173, no. 1, pp. 141–155, 1994.
[3] D. J. Prockop, “Marrow stromal cells as stem cells for nonhem-
atopoietic tissues,” Science, vol. 276, no. 5309, pp. 71–74, 1997.
[4] W. A. Noort, A. B. Kruisselbrink, P. S. In’t Anker et al.,
“Mesenchymal stem cells promote engraftment of human
umbilical cord blood-derived CD34+ cells in NOD/SCID
mice,” Experimental Hematology, vol. 30, no. 8, pp. 870–878,
2002.
[5] J. I. Morton and B. V. Siegel, “Transplantation of autoimmune
potential. I. Development of antinuclear antibodies in H-2
histocompatible recipients of bonemarrow fromNew Zealand
black mice,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 71, no. 6, pp. 2162–2165,
1974.
[6] Y. Jiang, B. N. Jahagirdar, R. L. Reinhardt et al., “Pluripotency
of mesenchymal stem cells derived from adult marrow,”
Nature, vol. 418, no. 6893, pp. 41–49, 2002.
[7] B. E. Petersen,W. C. Bowen, K. D. Patrene et al., “Bonemarrow
as a potential source of hepatic oval cells,” Science, vol. 284, no.
5417, pp. 1168–1170, 1999.
[8] R. E. Schwartz, M. Reyes, L. Koodie et al., “Multipotent
adult progenitor cells from bone marrow diﬀerentiate into
functional hepatocyte-like cells,” The Journal of Clinical Inves-
tigation, vol. 109, no. 10, pp. 1291–1302, 2002.
[9] J. I. Morton, B. V. Siegel, and R. D. Moore, “Multipotent
adult progenitor cells from bone marrow diﬀerentiate into
functional hepatocyte-like cells,” Transplantation, vol. 19, no.
6, pp. 464–469, 1975.
[10] M. D. Nicola, C. Carlo-Stella, M. Magni et al., “Human bone
marrow stromal cells suppress T-lymphocyte proliferation
induced by cellular or nonspecific mitogenic stimuli,” Blood,
vol. 99, no. 10, pp. 3838–3843, 2002.
[11] F. Djouad, P. Plence, C. Bony et al., “Immunosuppressive eﬀect
of mesenchymal stem cells favors tumor growth in allogeneic
animals,” Blood, vol. 102, no. 10, pp. 3837–3844, 2003.
[12] N. S. El-Badri, A. Hakki, A. Ferrari, R. Shamekh, and R. A.
Good, “Autoimmune disease: is it a disorder of the microen-
vironment?” Immunologic Research, vol. 41, no. 1, pp. 79–86,
2008.
[13] H. A. Papadaki, D. T. Boumpas, F. M. Gibson et al., “Increased
apoptosis of bone marrow CD34+ cells and impaired function
of bone marrow stromal cells in patients with systemic lupus
erythematosus,” British Journal of Haematology, vol. 115, no.
1, pp. 167–174, 2001.
[14] Y. Nie, C. S. Lau, A. K. W. Lie, G. C. F. Chan, and M. Y. Mok,
“Defective phenotype of mesenchymal stem cells in patients
with systemic lupus erythematosus,” Lupus, vol. 19, no. 7, pp.
850–859, 2010.
[15] L. Sun, K. Akiyama, H. Zhang et al., “Mesenchymal stem cell
transplantation reverses multiorgan dysfunction in systemic
lupus erythematosus mice and humans,” Stem Cells, vol. 27,
no. 6, pp. 1421–1432, 2009.
[16] L. Y. Sun, H. Y. Zhang, X. B. Feng, Y. Y. Hou, L. W. Lu, and L.
M. Fan, “Abnormality of bone marrow-derived mesenchymal
stem cells in patients with systemic lupus erythematosus,”
Lupus, vol. 16, no. 2, pp. 121–128, 2007.
[17] J. Liang, H. Zhang, and B. Hua, “Allogenic mesenchymal stem
cells transplantation in refractory systemic lupus erythemato-
sus: a pilot clinical study,” Annals of the Rheumatic Diseases,
vol. 69, no. 8, pp. 1423–1429, 2010.
[18] L. Sun, D. Wang, J. Liang et al., “Umbilical cord mesenchymal
stem cell transplantation in severe and refractory systemic
lupus erythematosus,” Arthritis and Rheumatism, vol. 62, no.
8, pp. 2467–2475, 2010.
[19] J. Liang, F. Gu, H. Wang et al., “Mesenchymal stem cell trans-
plantation for diﬀuse alveolar hemorrhage in SLE,” Nature
Reviews Rheumatology, vol. 6, no. 8, pp. 486–489, 2010.
[20] N. Zamurovic, D. Cappellen, D. Rohner, and M. Susa, “Co-
ordinated activation of Notch, Wnt, and transforming growth
factor-β signaling pathways in bone morphogenic protein 2-
induced osteogenesis: notch target gene Hey1 inhibits min-
eralization and Runx2 transcriptional activity,” The Journal of
Biological Chemistry, vol. 279, no. 36, pp. 37704–37715, 2004.
[21] Z. J. Wang, F. M. Zhang, L. S. Wang, Y. W. Yao, Q. Zhao,
and X. Gao, “Lipopolysaccharides can protect mesenchymal
stem cells (MSCs) from oxidative stress-induced apoptosis and
enhance proliferation of MSCs via Toll-like receptor(TLR)-4
and PI3K/Akt,” Cell Biology International, vol. 33, no. 6, pp.
665–674, 2009.
[22] F. Liotta, R. Angeli, L. Cosmi et al., “Toll-like receptors 3 and 4
are expressed by human bone marrow-derived mesenchymal
stem cells and can inhibit their T-cell modulatory activity by
impairing notch signaling,” Stem Cells, vol. 26, no. 1, pp. 279–
289, 2008.
[23] M. Pevsner-Fischer, V. Morad, M. Cohen-Sfady et al., “Toll-
like receptors and their ligands control mesenchymal stem cell
functions,” Blood, vol. 109, no. 4, pp. 1422–1432, 2007.
[24] E. M. Tan, A. S. Cohen, and J. F. Fries, “The 1982 revised
criteria for the classification of systemic lupus erythremato-
sus,” Arthritis and Rheumatism, vol. 25, no. 11, pp. 1271–1277,
1982.
[25] E. S. Schned, S. L. Glickstein, M. A. T. Doyle, C. Bombardier,
D. D. Gladman, and M. B. Urowitz, “Derivation of the
SLEDAI,” Arthritis and Rheumatism, vol. 36, no. 6, article 877,
1993.
[26] Y. Guo, H. Guo, L. Zhang et al., “Genomic analysis of anti-
hepatitis B virus (HBV) activity by small interfering RNA
and lamivudine in stable HBV-producing cells,” Journal of
Virology, vol. 79, no. 22, pp. 14392–14403, 2005.
[27] R. Li, H. Zhang, W. Yu et al., “ZIP: a novel transcription
repressor, represses EGFR oncogene and suppresses breast car-
cinogenesis,” The EMBO Journal, vol. 28, no. 18, pp. 2763–
2776, 2009.
12 Clinical and Developmental Immunology
[28] Y. Wang, H. Zhang, Y. Chen et al., “LSD1is a subunit of the
NuRD complex and targets the metastasis programs in breast
cancer,” Cell, vol. 138, no. 4, pp. 660–672, 2009.
[29] A. Nzeusseu Toukap, C. Galant, I. Theate et al., “Identification
of distinct gene expression profiles in the synovium of patients
with systemic lupus erythematosus,” Arthritis and Rheuma-
tism, vol. 56, no. 5, pp. 1579–1588, 2007.
[30] E. C. Baechler, F. M. Batliwalla, G. Karypis et al., “Interferon-
inducible gene expression signature in peripheral blood cells
of patients with severe lupus,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 100,
no. 5, pp. 2610–2615, 2003.
[31] L. Bennett, A. K. Palucka, E. Arce et al., “Interferon and gran-
ulopoiesis signatures in systemic lupus erythematosus blood,”
Journal of Experimental Medicine, vol. 197, no. 6, pp. 711–723,
2003.
[32] K. A. Kirou, C. Lee, S. George et al., “Coordinate over-
expression of interferon-α-induced genes in systemic lupus
erythematosus,” Arthritis and Rheumatism, vol. 50, no. 12, pp.
3958–3967, 2004.
[33] M. Nakou, N. Knowlton, M. B. Frank et al., “Gene expression
in systemic lupus erythematosus: bone marrow analysis
diﬀerentiates active from inactive disease and reveals apoptosis
and granulopoiesis signatures,” Arthritis and Rheumatism, vol.
58, no. 11, pp. 3541–3549, 2008.
[34] T. D. Pollard and G. G. Borisy, “Cellular motility driven by
assembly and disassembly of actin filaments,” Cell, vol. 113,
no. 4, article 549, 2003.
[35] N. A. Dye and L. Shapiro, “The push and pull of the bacterial
cytoskeleton,” Trends in Cell Biology, vol. 17, no. 5, pp. 239–
245, 2007.
[36] S. R. White, P. Williams, K. R. Wojcik et al., “Initiation
of apoptosis by actin cytoskeletal derangement in human
airway epithelial cells,” American Journal of Respiratory Cell
and Molecular Biology, vol. 24, no. 3, pp. 282–294, 2001.
[37] O.-M. Mykka¨nen, M. Gro¨nholm, M. Ro¨nty et al., “Char-
acterization of human palladin, a microfilament-associated
protein,” Molecular Biology of the Cell, vol. 12, no. 10, pp.
3060–3073, 2001.
[38] D. Chen, M. Zhao, and G. R. Mundy, “Bone morphogenetic
proteins,” Growth Factors, vol. 22, no. 4, pp. 233–241, 2004.
[39] H. H. Luu, W. X. Song, X. Luo et al., “Distinct roles of
bone morphogenetic proteins in osteogenic diﬀerentiation of
mesenchymal stem cells,” Journal of Orthopaedic Research, vol.
25, no. 5, pp. 665–677, 2007.
[40] T. Matsubara, K. Kida, A. Yamaguchi et al., “BMP2 regulates
osterix through Msx2 and Runx2 during osteoblast diﬀerenti-
ation,” The Journal of Biological Chemistry, vol. 283, no. 43, pp.
29119–29125, 2008.
[41] W. Leeanansaksiri, H. Wang, J. M. Gooya et al., “IL-3 induces
inhibitor of DNA-binding protein-1 in hemopoietic progeni-
tor cells and promotes myeloid cell development,” Journal of
Immunology, vol. 174, no. 11, pp. 7014–7021, 2005.
[42] X. Feng, R. Li, J. Huang et al., “Olf1/EBF associated zinc
finger protein interfered with antinuclear antibody production
in patients with systemic lupus erythematosus,” Arthritis
Research and Therapy, vol. 12, no. 2, article R59, 2010.
[43] K. Maeda, A. Malykhin, B. N. Teague-Weber, X. H. Sun, A. D.
Farris, and K. M. Coggeshall, “Interleukin-6 aborts lympho-
poiesis and elevates production of myeloid cells in systemic
lupus erythematosus-prone B6.Sle1.Yaa animals,” Blood, vol.
113, no. 19, pp. 4534–4540, 2009.
[44] A. Studnicka-Benke, G. Steiner, P. Petera, and J. S. Smolen,
“Tumour necrosis factor alpha and its soluble receptors
parallel clinical disease and autoimmune activity in systemic
lupus erythematosus,” British Journal of Rheumatology, vol. 35,
no. 11, pp. 1067–1074, 1996.
[45] M. Aringer and J. S. Smolen, “Complex cytokine eﬀects in a
complex autoimmune disease: tumor necrosis factor in sys-
temic lupus erythematosus,” Arthritis Research and Therapy,
vol. 5, no. 4, pp. 172–177, 2003.
[46] H. Gao, W. Priebe, J. Glod, and D. Banerjee, “Activation of
signal transducers and activators of transcription 3 and focal
adhesion kinase by stromal cell-derived factor 1 is required for
migration of human mesenchymal stem cells in response to
tumor cell-conditioned medium,” Stem Cells, vol. 27, no. 4,
pp. 857–865, 2009.
[47] J. Caverzasio and D. Manen, “Essential role of Wnt3a-
mediated activation of mitogen-activated protein kinase p38
for the stimulation of alkaline phosphatase activity and matrix
mineralization in C3H10T1/2mesenchymal cells,” Endocrinol-
ogy, vol. 148, no. 11, pp. 5323–5330, 2007.
[48] A. Hoﬀmann, O. Preobrazhenska, C. Wodarczyk et al.,
“Transforming growth factor-β-activated kinase-1 (TAK1), a
MAP3K, interacts with Smad proteins and interferes with
osteogenesis in murine mesenchymal progenitors,” The Jour-
nal of Biological Chemistry, vol. 280, no. 29, pp. 27271–27283,
2005.
[49] M. Yamashita, F. Otsuka, T. Mukai et al., “Simvastatin
antagonizes tumor necrosis factor-α ihibition of bone mor-
phogenetic proteins-2-induced osteoblast diﬀerentiation by
regulating Smad signaling and Ras/Rho-mitogen-activated
protein kinase pathway,” Journal of Endocrinology, vol. 196, no.
3, pp. 601–613, 2008.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
